Sloan, A., Buerki, R., Landi, D., Desjardins, A., Friedman, A., Ambady, P., … Nichols, W. G. (2021). CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. In Neuro-Oncology (Vol. 23, pp. vi53–vi54). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noab196.210

Sloan, Andrew, Robin Buerki, Daniel Landi, Annick Desjardins, Allan Friedman, Prakash Ambady, Kevin Becker, et al. “CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA.” In Neuro-Oncology, 23:vi53–54. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.210.

Sloan A, Buerki R, Landi D, Desjardins A, Friedman A, Ambady P, et al. CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. In: Neuro-Oncology. Oxford University Press (OUP); 2021. p. vi53–4.

Sloan, Andrew, et al. “CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA.” Neuro-Oncology, vol. 23, no. Supplement_6, Oxford University Press (OUP), 2021, pp. vi53–54. Crossref, doi:10.1093/neuonc/noab196.210.

Sloan A, Buerki R, Landi D, Desjardins A, Friedman A, Ambady P, Becker K, Butowski N, Cavaliere R, Curry W, Ong S, Vega R, Wen P, Bockorny B, Chiocca EA, Elder JB, Bulsara K, Berger M, Gerstner E, Sauvageau E, Kelly A, Mixson L, Jackson L, Learn C, Dickinson A, Nichols WG. CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. Oxford University Press (OUP); 2021. p. vi53–vi54.